StageZero Life Sciences Ltd T.SZLS

RE:RE:RE:Breast cancer announcement

[polo11]

BreastSentry®: pro-NT and pro-ENK biomarkers

In October 2014 we in-licensed two blood based biomarker assays—pro-NT and pro-ENK—that may aid physicians in identifying those women who are at risk for developing breast cancer. These assays were developed by sphingotec GmbH, known for the discovery and development of biomarker assays.

Breast cancer is the second leading cause of cancer deaths in women in the United States and is exceeded only by lung cancer. The American Cancer Society estimates that in 2016 approximately 246,660 new cases of invasive breast cancer will be diagnosed in women and approximately 40,450 women will die from the disease. As with most cancers, early identification of high-risk patients and intervention are the keys to improved clinical outcomes.

Many breast cancer cases are not due to genetic inheritance and, unlike other blood tests on the market that look for genetic indicators for breast cancer, pro-NT and pro-ENK are biomarkers that, when measured in a convenient blood test, indicate the level of a woman’s risk for breast cancer. The tests may be particularly applicable to those 40% of women who have dense breast tissue and where mammograms have less utility. BreastSentry®, the name under which we expect to market the completed test, is being validated as a laboratory developed test at IDL and prepared for a market entry early in 2017.